Merck is likely to climb, even as its patent for popular cancer drug Keytruda is getting closer to expiring, according to Morgan Stanley. The investment bank upgraded the stock to overweight from ...

Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a ...

Shares closed up a remarkable 177% in a single day, adding to a rally that has seen the stock climb some 465% so far this year. For a company whose fortunes had faded badly since its pandemic-era ...

BioAge's diversified pipeline includes ophthalmology and apelin-APJ pathway programs, and partnerships with Novartis and Eli ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Find the best wet cat food for kittens, adults, and seniors, selected with guidance from veterinarians and board-certified ...

The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease ...

Cardiologists are struggling to figure out why a drug that should have prevented heart attacks didn’t work at all.

Doctors were hopeful the drug, which was being tested in a large clinical trial by Novartis, was going to be a powerful new ...

Shares of Novartis fell more than 3% on Monday after its cholesterol drug failed in a closely watched study, dealing ‌a blow ...

Leo Pharma A/S agreed to buy the global rights to a drug in late-stage development to treat two rare genetic skin diseases, adding to a series of deals as the Danish drugmaker positions for an initial ...

By Ellyn Vohnoutka HealthDay ReporterWEDNESDAY, Sept. 9, 2026 (HealthDay News) — A drug that heart doctors widely expected to become the next major weapon against heart attacks has failed in a large ...